Low density lipoprotein (LDL) was incubated with 20 gIM of the angiotensin converting enzyme (ACE) inhibitors captopril, fosinopril and quinapril or ethanol. Oxidation of LDL was initiated by addition of CuSO4 and monitored for production of conjugated dienes, thiobarbituric acid reactive substances (TBARS) and lipid peroxides. The inhibition of production of conjugated dienes was expressed as the lag phase in minutes. The lag phase for control samples was 55.2 ± 6.1 (mean ± s.e. mean) min and for captopril 86.4 ± 7.0 min (P = 0.0058). Quinapril had a small but nonsignificant effect, fosinopril and ethanol had no effect. LDL incubated with captopril showed only 13.8% of TBARS and 22.7% of lipid peroxides produced by control (100%) after 1 h. Increasing concentrations of captopril showed a linear increase in the lag phase. We conclude that captopril increases the resistance of LDL to copperinduced oxidation.
Introduction
Oxidatively modified low density lipoproteins (ox-LDL) have been suggested to be important in the pathogenesis of atherosclerosis. Ox-LDL are taken up rapidly via the scavenger receptor expressed by macrophages. This uptake is said to explain the accumulation of lipids in the fatty streak, which is thought to precede more advanced atherosclerotic lesions [1] . A possible way of inhibiting or delaying this oxidation would be to administer antioxidants. Recently it was found that two inhibitors of angiotensin converting enzyme (ACE), captopril and fosinopril, both reduce experimentally induced atherosclerotic lesions in hypercholesterolaemic mini-pigs [2] , although the effect was much more pronounced for captopril. This effect was supposed to be due partly to free radical scavenging by the sulphydryl (SH-) group in the captopril molecule acting as an antioxidant.
The aim of this study was to test the hypothesis that LDL incubated in vitro with captopril or other ACE inhibitors, could delay the oxidation of LDL.
ACE inhibitors captopril quinapril

Methods
Fresh whole blood was obtained from seven healthy volunteers by venepuncture after an overnight fast.
The blood was collected in EDTA (1.4 mg ml-') containing tubes and immediately cooled. Plasma was centrifuged at 1700 g for 15 min. LDL was obtained by preparative ultracentrifugation within a density gradient of 1.020-1.050 g cm-3 [3] . ance was monitored at 234 nm every 5 min for 2-4 h at +37°C [4] . The lag phase (min) was defined as the intercept of the slope during the propagation phase with the initial absorbance axis. The intraassay error was less than 6%.
Gel-filtered LDL 50 ,ug ml-' was then incubated with increasing concentrations of captopril. Oxidation was initiated and monitored as described above.
Determination of thiobarbituric acid reactive substances (TBARS) was performed as described by Buege & Aust [5] and lipid peroxides according to El-Saadani [6] . In summary, dialyzed LDL Lowry [7] .
Values are given as means and standard error of the mean (s.e. mean). Statistically significant differences between control and the ACE inhibitors were considered at P < 0.05 using Student's unpaired t-test.
Results
When LDL was incubated with fosinopril or ethanol in vitro, no prolongation of the lag phase was seen as compared with control (Table 1 
Discussion
The mechanisms responsible for the dramatic antioxidant effect of captopril with a pronounced pro- 59.1 ± 2.9 58.9 ± 5.5 *P < 0.05, **P < 0.01, ***P < 0.001 vs control.
For lag phase determination (n = 7), 50 ig ml-' LDL was incubated with 20 gM of the ACE-inhibitor or ethanol.
Oxidation was initiated with 10 JM CuS04. For TBARS (n = 7) and lipid peroxides (n = 6) twice the concentration of all components were used.
longation of the lag phase are not completely understood. Extensive studies on the antioxidant action of captopril have been carried out by Chopra et al. [8] . According to them the thiol-group is the site of free radical scavenging. It has also been discussed that captopril itself might possess copperchelating properties [9] . Our experiment supports the findings of Chopra et al. [8] . The clinical relevance of our observations is difficult to evaluate at present. Based on our earlier detailed pharmacokinetic studies of captopril and its effects on blood pressure in hypertensive patients [10] , the incubation concentrations used in the present study (5-50 gM) may be somewhat high. We measured plasma concentrations in these patients up to 5 gM (2-3 h after drug administration) but the captopril doses used (25-75 mg day-') were lower than those now recommended (150 mg day-) for the prevention of progression of left ventricular dysfunction [11] . Thus, the incubation concentrations used here may be relevant both physiologically and clinically. Our earlier experience with captopril (as compared with fosinopril) as an antiatherogenic agent in cholesterol-fed pigs [2] may also indicate that the SH-group in the captopril molecule is responsible for the anti-atherosclerotic effect.
Further investigations, including in vivo studies, are necessary to confirm the clinical relevance of a prolonged lag phase. This may be relevant to the future role of captopril as an antioxidant agent and its potential as an anti-atherogenic agent.
